# CJC-1295 Peptide

> CJC-1295 is a long-acting GHRH analog that stimulates pituitary GH signaling, raises GH and IGF-1 biomarkers, and extends GH-axis activity.

Canonical: https://pepflow.app/peptides/cjc-1295/

The GH Pulse Extender

A long-acting growth-hormone-releasing hormone analog designed to bind albumin and extend GH-axis signaling, best known for sustained GH and IGF-1 biomarker increases after subcutaneous dosing.

Anti-aging  Lean mass  Recovery  Sleep  Body composition

Tier B

Evidence Moderate

Safety Moderate Data

FDA status Not Approved

Last reviewed August 11, 2026 21 citations [How to read these labels](<https://pepflow.app/peptide-label-legend/>)

## What is CJC-1295?

CJC-1295 is a synthetic growth-hormone-releasing hormone (GHRH) analog built from the active hGRF(1-29) sequence. Its amino-acid substitutions and albumin-binding extension are designed to resist breakdown and keep the pituitary GHRH signal active longer than native GHRH fragments.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/15817669/>) [\[16\]](<https://www.fda.gov/media/183819/download>)

The defining feature is its albumin-binding tail. After injection, that group can attach to circulating albumin, which acts like a carrier protein in blood; this is why CJC-1295 is discussed as the long-acting form while Modified GRF 1-29 is treated as shorter acting.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/15817669/>) [\[16\]](<https://www.fda.gov/media/183819/download>)

Biologically, CJC-1295 does not replace growth hormone directly. It stimulates the pituitary GHRH receptor pathway, and human studies show downstream GH and IGF-1 biomarker increases when the pituitary GH axis can respond.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/17018654/>)

The naming can be messy. CJC-1295, CJC-1295 without DAC, Modified GRF 1-29, and blends with GH secretagogues are not interchangeable; this page uses CJC-1295 to mean the long-acting albumin-binding form unless a section says otherwise.[\[16\]](<https://www.fda.gov/media/183819/download>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/15817669/>) For more context, read the [CJC-1295 DAC and no-DAC comparison](<https://pepflow.app/blog/cjc-1295-dac-vs-no-dac/>).

## What CJC-1295 is investigated for

CJC-1295 evidence is grouped by practical use case and injectable route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

### ### GH-axis stimulation and IGF-1 biomarker response Injectable 68% Moderate

This is the best-supported CJC-1295 claim: human evidence shows sustained GH and IGF-1 biomarker response after subcutaneous dosing.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/17018654/>)

#### Human evidence

In healthy adults, subcutaneous CJC-1295 produced dose-dependent mean plasma GH increases of 2- to 10-fold for six days or more and mean plasma IGF-1 increases of 1.5- to 3-fold for 9-11 days after single dosing. A separate study found increased trough and mean GH with preserved pulsatility.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/17018654/>)

#### Animal / mechanistic evidence

Preclinical work identified CJC-1295 as a long-lasting hGRF(1-29) analog that conjugates to albumin and remains detectable longer than native GHRH fragments in rats. Mouse GHRH-knockout work supports GH-axis biological activity in a deficiency model.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/15817669/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/16822960/>)

### ### Lean-mass and fat-loss support Injectable 45% Preliminary

Lean-mass and fat-loss support are biologically plausible for CJC-1295 because the peptide sustains GH and IGF-1 signaling, but direct human outcome evidence remains weak.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/16822960/>)

#### Human evidence

Interest centers on lean-mass support, fat-mass changes, and weight-trend changes downstream of GH and IGF-1 signaling. Human CJC-1295 studies show sustained GH and IGF-1 biomarker increases, but they did not establish controlled DEXA, waist, visceral-fat, or fat-loss outcomes.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/17018654/>)

#### Animal / mechanistic evidence

In a GHRH-knockout mouse deficiency model, daily CJC-1295 supported normal growth and tissue-mass-related measures. That strengthens the GH-axis rationale, but it is not the same as healthy-adult lean-mass or fat-loss evidence.[\[5\]](<https://pubmed.ncbi.nlm.nih.gov/16822960/>)

### ### Exercise recovery and training adaptation Injectable 18% Insufficient

Recovery is commonly discussed with CJC-1295, but it should be shown as an indirect GH-axis claim until outcome-specific human evidence is available.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>) [\[4\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC2787983/>)

#### Human evidence

No reviewed controlled human CJC-1295 trial shows faster exercise recovery, injury recovery, strength gains, or training adaptation. Human support is indirect: the peptide can raise GH and IGF-1 biomarkers that readers associate with repair and recovery biology.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>) [\[4\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC2787983/>)

#### Animal / mechanistic evidence

Animal and mechanistic work supports prolonged GHRH signaling and GH-axis activity, but the reviewed CJC-1295 animal data are not sports-injury or training-adaptation studies.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/15817669/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/16822960/>)

### ### Sleep quality Injectable 16% Insufficient

Sleep quality is a common tracking claim for CJC-1295, but the current evidence supports GH-axis physiology, not a proven sleep benefit.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/17018654/>)

#### Human evidence

CJC-1295 has not shown controlled sleep-quality outcomes in the reviewed human evidence. The sleep rationale comes from overnight GH physiology and preserved GH pulsatility, not from validated sleep endpoints.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/17018654/>)

#### Animal / mechanistic evidence

The reviewed preclinical evidence supports CJC-1295 duration and GH-axis activity rather than sleep architecture, sleep latency, REM, deep sleep, or insomnia outcomes.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/15817669/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/16822960/>)

### ### Anti-aging and vitality support Injectable 14% Insufficient

Anti-aging and vitality belong on the page because readers search for them, but they should remain low-confidence outcome claims rather than proven benefits.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>) [\[4\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC2787983/>)

#### Human evidence

Human CJC-1295 studies show endocrine biomarker changes, not longevity, healthspan, age reversal, skin aging, frailty, or vitality outcomes. Anti-aging claims are downstream interpretations that need their own human outcome data.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>) [\[4\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC2787983/>)

#### Animal / mechanistic evidence

The reviewed animal evidence supports GH-axis signaling and albumin-linked duration. It does not establish lifespan, healthspan, senescence, or age-related functional benefits.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/15817669/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/16822960/>)

## Evidence snapshot

### Overall confidence

Moderate

65%

CJC-1295 has stronger human biomarker evidence than many research peptides, but weaker clinical-outcome evidence than approved GH-axis drugs. The best-supported statement is that it can sustain GH and IGF-1 biomarker increases after subcutaneous administration.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/17018654/>) [\[17\]](<https://api.fda.gov/drug/drugsfda.json?search=openfda.substance_name:%22CJC-1295%22+OR+products.active_ingredients.name:%22CJC-1295%22&limit=1>)

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

70%

### Human evidence

Moderate

Human pharmacodynamic support is strongest for GH and IGF-1 biomarkers: GH rose for six days or more, IGF-1 rose for 9-11 days after single dosing, and repeated dosing kept mean IGF-1 above baseline for up to 28 days.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>)

50%

### Animal / preclinical

Limited

Animal studies support the albumin-binding GHRH mechanism. Rat work identified CJC-1295 as a long-lasting hGRF(1-29) analog, and GHRH-knockout mice treated once daily maintained normal growth and body composition. This supports GH-axis pharmacology, not human outcome claims.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/15817669/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/16822960/>)

68%

### Mechanism support

Moderate

Mechanistic support is coherent: CJC-1295 is a modified GHRH analog, the DAC form binds albumin, and human studies show GH-axis activation. FDA notes that DAC and non-DAC forms should not be treated as interchangeable.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/15817669/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/17018654/>) [\[16\]](<https://www.fda.gov/media/183819/download>)

## Forms & administration

CJC-1295 is primarily discussed as a subcutaneous, long-acting GHRH analog. Route, albumin-binding form, concentration, product quality, and monitoring matter because sustained GH/IGF-1 signaling depends on systemic exposure.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>) [\[16\]](<https://www.fda.gov/media/183819/download>) [\[15\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)

Injectable

## Dosing & protocols

These ranges are general reference points, not personal dosing instructions.

### Typical Range

Common injectable protocols use 2 mg per dose.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>) [\[16\]](<https://www.fda.gov/media/183819/download>)

### Frequency

Usually taken 2-3 times per week.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>) [\[16\]](<https://www.fda.gov/media/183819/download>)

### Timing Considerations

Before bed is the usual timing.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/17018654/>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>)

### Cycle Length

Common cycles run 8-12 weeks.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>)

[Full CJC-1295 dosage guide](<https://pepflow.app/peptides/cjc-1295/dosage/>)

## What to expect

### First week

Early sustained GH and IGF-1 biomarker elevation after subcutaneous dosing, with practical notes around sleep, recovery, water retention, and appetite.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/17018654/>)

### Days 9-11

Persistent mean plasma IGF-1 increases after a single CJC-1295 dose, which is why albumin-binding CJC-1295 is scheduled differently from short-acting GHRH analogs.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>)

### Weeks 4-12

Sustained GH/IGF-1 lab movement, weight trend, body-composition notes, sleep, training tolerance, and recovery patterns against baseline.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>) [\[15\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)

### After stopping

Gradual return-toward-baseline pattern for GH/IGF-1 biomarkers, weight, sleep notes, and training markers after long-acting exposure ends.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>) [\[15\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)

## Safety profile

CJC-1295 safety should be treated as endocrine-active, route-specific, and unresolved for long-term non-study use. Early human studies reported no serious adverse reactions, but FDA later identified serious adverse events associated with CJC-1295, limited clinical data, and peptide compounding concerns around immunogenicity, impurities, and API characterization.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>) [\[15\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) [\[16\]](<https://www.fda.gov/media/183819/download>)

### Common side effects

- Injection-site pain or swelling [\[16\]](<https://www.fda.gov/media/183819/download>)
- Flushing or warmth [\[15\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)
- Low blood pressure [\[15\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)
- Faster heart rate [\[15\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)
- Headache [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>) [\[16\]](<https://www.fda.gov/media/183819/download>)
- Gastrointestinal symptoms [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>) [\[16\]](<https://www.fda.gov/media/183819/download>)

### Cautions

- Endocrine medical supervision[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/17018654/>)
- Unapproved product quality[\[15\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) [\[16\]](<https://www.fda.gov/media/183819/download>)
- Prohibited in sport

### What we don't know

Decision-changing unknowns include long-term safety, repeated non-study use, product interchangeability, DAC versus no-DAC risk differences, cancer- or growth-factor-sensitive conditions, special-population safety, and whether outcome benefits justify endocrine exposure.[\[15\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) [\[16\]](<https://www.fda.gov/media/183819/download>)

## Who CJC-1295 is not for

Route-specific avoid and medical-review notes:

- **Competitive athletes**

  Competitive athletes should avoid CJC-1295 unless their anti-doping authority provides route-specific written clearance. WADA lists CJC-1295 as prohibited under growth hormone releasing factors.
- **Endocrine disease or glucose dysregulation**

  Medical review is needed in endocrine disease, diabetes, insulin resistance, or unexplained abnormal IGF-1/GH-related labs because CJC-1295 acts through the GH/IGF-1 axis.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/17018654/>)
- **Cancer or growth-factor-sensitive conditions**

  This is a medical-review caution, not a documented CJC-1295 cancer-outcome finding. Because the peptide raises IGF-1 biomarkers, growth-factor-sensitive histories should not be handled through self-directed use.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>) [\[15\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)
- **Pregnancy, breastfeeding, or pediatric use**

  Pregnancy, breastfeeding, and pediatric use are not supported by route-specific CJC-1295 safety data.[\[15\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) [\[16\]](<https://www.fda.gov/media/183819/download>)

## Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

### Theoretical interactions

- **Other GH-axis drugs or secretagogues**

  This is a theoretical additive-exposure caution. Combining CJC-1295 with other GH-axis agents, growth hormone, GHRPs, or secretagogues may make GH/IGF-1 exposure and side-effect interpretation harder to manage.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/17018654/>) [\[15\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)
- **Glucose-active medications**

  This is a theoretical endocrine-monitoring caution. Because GH/IGF-1 signaling intersects with metabolic regulation, people using insulin, diabetes drugs, or weight-management medications need clinician review rather than app-only scheduling.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>)

## Pairing notes

### Commonly included in these stacks

[**Long-Acting GH Stack** Long-Acting GH Stack pairs CJC-1295 DAC with Ipamorelin, combining a long-acting GHRH analog with a selective ghrelin-receptor growth-hormone secretagogue. The practical rationale is dual upstream stimulation of the GH/IGF-1 axis. CJC-1295 Ipamorelin](<https://pepflow.app/stacks/cjc-1295-ipamorelin/>)

### Not recommended with

**Somatropin: compounded GH/IGF-1 effects** Injectable

This pairing compounds GH/IGF-1 stimulation through direct growth hormone plus an upstream release signal, increasing the need to review IGF-1, glucose, fluid retention, joint symptoms, and the reason for using both.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>) [\[16\]](<https://www.fda.gov/media/183819/download>) [\[18\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>)

**CJC-1295 No DAC: overlapping GHRH signaling** Injectable

CJC variants provide different exposure profiles but stimulate the same GHRH receptor pathway. Combining them duplicates GH/IGF-1 stimulation and makes exposure and monitoring harder to interpret.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>) [\[19\]](<https://pubmed.ncbi.nlm.nih.gov/7962295/>) [\[16\]](<https://www.fda.gov/media/183819/download>)

**Tesamorelin: overlapping GHRH signaling** Injectable

Tesamorelin and CJC-1295 both stimulate GHRH receptors to increase growth-hormone and IGF-1 signaling. Using both duplicates the same upstream GH-axis mechanism without an established combined regimen.[\[20\]](<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>) [\[16\]](<https://www.fda.gov/media/183819/download>)

**Sermorelin: overlapping GHRH signaling** Injectable

Sermorelin and CJC-1295 both stimulate the GHRH receptor. CJC-1295 extends exposure, but overlapping the two still duplicates upstream GH/IGF-1 stimulation.[\[21\]](<https://pubmed.ncbi.nlm.nih.gov/8772599/>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>) [\[16\]](<https://www.fda.gov/media/183819/download>)

### Related peptides

[CJC-1295 (no DAC)](<https://pepflow.app/peptides/cjc-1295-no-dac/>)

## Regulatory status

### United States

United States: not FDA-approved for human use as a drug. FDA PCAC materials state that the reviewed CJC-1295-related substances are not components of an FDA-approved drug, and FDA lists CJC-1295 among nominated-but-withdrawn bulk substances with safety concerns.[\[17\]](<https://api.fda.gov/drug/drugsfda.json?search=openfda.substance_name:%22CJC-1295%22+OR+products.active_ingredients.name:%22CJC-1295%22&limit=1>) [\[16\]](<https://www.fda.gov/media/183819/download>) [\[15\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)

| Route | FDA drug approval | 503A compounding |
| --- | --- | --- |
| Injectable | Not Approved · The openFDA Drugs@FDA query for CJC-1295 returned no matching approved drug product, and FDA PCAC materials state that the reviewed CJC-1295-related substances are not components of an FDA-approved drug.[\[17\]](<https://api.fda.gov/drug/drugsfda.json?search=openfda.substance_name:%22CJC-1295%22+OR+products.active_ingredients.name:%22CJC-1295%22&limit=1>) [\[16\]](<https://www.fda.gov/media/183819/download>) | Flagged · FDA's safety-risk page lists CJC-1295 under bulk substances nominated but withdrawn and flags immunogenicity for certain routes, peptide-related impurities, API-characterization complexity, serious adverse events including increased heart rate and systemic vasodilatory reaction, and limited clinical data.[\[15\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) [\[16\]](<https://www.fda.gov/media/183819/download>) |

### Injectable

FDA drug approval

Not Approved

The openFDA Drugs@FDA query for CJC-1295 returned no matching approved drug product, and FDA PCAC materials state that the reviewed CJC-1295-related substances are not components of an FDA-approved drug.[\[17\]](<https://api.fda.gov/drug/drugsfda.json?search=openfda.substance_name:%22CJC-1295%22+OR+products.active_ingredients.name:%22CJC-1295%22&limit=1>) [\[16\]](<https://www.fda.gov/media/183819/download>)

503A compounding

Flagged

FDA's safety-risk page lists CJC-1295 under bulk substances nominated but withdrawn and flags immunogenicity for certain routes, peptide-related impurities, API-characterization complexity, serious adverse events including increased heart rate and systemic vasodilatory reaction, and limited clinical data.[\[15\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) [\[16\]](<https://www.fda.gov/media/183819/download>)

### International

International status is route-, product-, and claim-specific. No country-specific therapeutic approval outside the United States is established in this review.

### Sports & competition

Sports competition: prohibited under WADA S2 growth hormone releasing factors. The prohibition applies regardless of whether the product is labeled as research use, compounded, or clinic supplied.

## How it works

The starting point is the natural GHRH signal. GHRH normally tells pituitary somatotroph cells to release growth hormone. CJC-1295 is designed to imitate and extend that signal rather than replace GH itself.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/17018654/>) [\[16\]](<https://www.fda.gov/media/183819/download>)

The albumin-binding feature changes the pharmacology. Jette and colleagues used a maleimido albumin-binding strategy, and FDA review materials describe the MPA group binding covalently to albumin's cysteine-34 residue. In plain terms, albumin works like a circulation carrier that can make the signal last much longer.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/15817669/>) [\[16\]](<https://www.fda.gov/media/183819/download>)

In human studies, that design translated into sustained endocrine biomarkers: GH rose for days, IGF-1 rose for longer, and pulsatile GH secretion was preserved while baseline trough GH increased. Those details matter because a flat GH replacement exposure and a stimulated pituitary signal are not the same thing.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/17018654/>)

The limitation is translation. GH and IGF-1 sit upstream of body composition, recovery, and sleep biology, but raising upstream biomarkers does not automatically prove a downstream outcome. Stronger claims require outcome trials, long-term safety data, and route-specific product-quality evidence.[\[4\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC2787983/>) [\[15\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)

## Research gaps & open questions

What the current literature has not yet settled about CJC-1295:

01

Controlled trials still need to show whether CJC-1295 improves fat loss, lean mass, sleep, recovery, or symptoms—not only growth hormone and IGF-1 blood levels.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>)

02

Long-term safety remains unclear, especially with repeated use or persistently high IGF-1 in people with endocrine disease, blood-sugar problems, cancer risk, or other special health considerations.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>) [\[15\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)

03

Independent testing needs to show the identity, purity, stability, and immune-reaction risk of compounded CJC-1295 products.[\[15\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) [\[16\]](<https://www.fda.gov/media/183819/download>)

04

The DAC and no-DAC forms need separate dosing, safety, and evidence guidance; they should not be treated as interchangeable.[\[16\]](<https://www.fda.gov/media/183819/download>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/15817669/>)

## Common questions

### What is CJC-1295 investigated for?

CJC-1295 is commonly investigated or discussed across GH-axis stimulation, body-composition outcomes, exercise recovery, sleep quality, and anti-aging or vitality support. The strongest direct support is GH and IGF-1 biomarker response; the other outcome areas need their own human evidence.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/17018654/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/16822960/>) [\[4\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC2787983/>)

### Is CJC-1295 the same as CJC-1295 without DAC?

No. CJC-1295 is the long-acting albumin-binding form. CJC-1295 without DAC is usually discussed as Modified GRF 1-29, a shorter-acting GHRH analog with different scheduling and evidence questions.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/15817669/>) [\[16\]](<https://www.fda.gov/media/183819/download>)

### What is the CJC-1295 dose?

Common CJC-1295 protocols usually center on 2 mg per dose, 2-3 times weekly, before bed, for 8-12 weeks.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>) [\[16\]](<https://www.fda.gov/media/183819/download>)

### Is CJC-1295 safe?

The safety answer is not settled. Early healthy-adult studies reported no serious adverse reactions, but FDA identifies limited clinical data, serious adverse events associated with CJC-1295, and compounding concerns involving immunogenicity, impurities, and API characterization.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>) [\[15\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)

### Can CJC-1295 be combined with ipamorelin?

CJC-1295 and ipamorelin act through different GH-axis pathways, but combination-level efficacy, safety, dosing, lab monitoring, and sports status need a separate stack review before the pair is treated as recommended.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>) [\[15\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)

## Myths & misconceptions

### Myth

If CJC-1295 raises GH and IGF-1, it is proven for muscle, sleep, recovery, and anti-aging.

### Reality

The reviewed human data prove endocrine biomarker response, not the full set of marketed outcomes. Each downstream claim needs its own human outcome evidence.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>) [\[4\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC2787983/>)

### Myth

Long-acting CJC-1295 and CJC-1295 no DAC are basically the same.

### Reality

They should be treated as different pharmacology problems. FDA review materials distinguish DAC and non-DAC CJC-1295-related substances and caution that albumin-binding pharmacology cannot be extrapolated to the non-DAC form.[\[16\]](<https://www.fda.gov/media/183819/download>)

### Myth

Research-use or compounded CJC-1295 is safe if the schedule looks common.

### Reality

A familiar schedule does not solve product identity, sterility, peptide-related impurities, aggregation, immunogenicity, API characterization, or long-term endocrine safety.[\[15\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) [\[16\]](<https://www.fda.gov/media/183819/download>)

## History & discovery

CJC-1295 moved from albumin-binding GHRH analog design into early human GH-axis trials, then into discontinued drug-development and later compounding/research-market visibility. Its public reputation now runs ahead of completed clinical outcome evidence.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/15817669/>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>) [\[15\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)

Jette and colleagues identified CJC-1295 as a long-lasting hGRF(1-29) analog after testing maleimido hGRF-albumin bioconjugates in vitro and in rats.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/15817669/>)

Randomized, placebo-controlled ascending-dose studies in healthy adults reported sustained GH and IGF-1 increases after subcutaneous CJC-1295, and a separate study reported preserved GH pulsatility.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/17018654/>)

A serum proteomics study examined biomarker changes after CJC-1295 exposure, while analytical work identified CJC-1295 in an unknown pharmaceutical preparation and framed it as a WADA-prohibited GH-releasing factor.[\[4\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC2787983/>) [\[13\]](<https://pubmed.ncbi.nlm.nih.gov/21204297/>)

FDA PCAC materials evaluated five CJC-1295-related bulk substances for 503A compounding and FDA's safety-risk page lists CJC-1295 under nominated-but-withdrawn substances. WADA's 2026 prohibited-list materials identify CJC-1295 as a prohibited growth hormone releasing factor.[\[16\]](<https://www.fda.gov/media/183819/download>) [\[15\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)

## Published research 21 citations

- [\[1\] **Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.** PubMed / Journal of Clinical Endocrinology and Metabolism, 2006. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/16352683/>)
- [\[2\] **Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.** PubMed / Journal of Clinical Endocrinology and Metabolism, 2006. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/17018654/>)
- [\[3\] **Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog.** PubMed / Endocrinology, 2005. animal.](<https://pubmed.ncbi.nlm.nih.gov/15817669/>)
- [\[4\] **Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.** PubMed Central / Growth Hormone & IGF Research, 2009. human clinical.](<https://pmc.ncbi.nlm.nih.gov/articles/PMC2787983/>)
- [\[5\] **Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.** PubMed / American Journal of Physiology-Endocrinology and Metabolism, 2006. animal.](<https://pubmed.ncbi.nlm.nih.gov/16822960/>)
- [\[6\] **Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications.** PubMed / JBJS Reviews, 2026. review.](<https://pubmed.ncbi.nlm.nih.gov/42160466/>)
- [\[7\] **Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.** PubMed / Sports Medicine, 2026. review.](<https://pubmed.ncbi.nlm.nih.gov/41966639/>)
- [\[8\] **Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.** PubMed / American Journal of Sports Medicine, 2026. review.](<https://pubmed.ncbi.nlm.nih.gov/41476424/>)
- [\[9\] **Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions.** PubMed / Substance Use & Misuse, 2016. review.](<https://pubmed.ncbi.nlm.nih.gov/26771670/>)
- [\[10\] **Advances in the detection of growth hormone releasing hormone synthetic analogs.** PubMed / Drug Testing and Analysis, 2021. ex vivo.](<https://pubmed.ncbi.nlm.nih.gov/34665524/>)
- [\[11\] **An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma.** PubMed / Drug Testing and Analysis, 2019. ex vivo.](<https://pubmed.ncbi.nlm.nih.gov/30489688/>)
- [\[12\] **A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS.** PubMed / Drug Testing and Analysis, 2019. ex vivo.](<https://pubmed.ncbi.nlm.nih.gov/30938069/>)
- [\[13\] **Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation.** PubMed / Drug Testing and Analysis, 2010. regulatory.](<https://pubmed.ncbi.nlm.nih.gov/21204297/>)
- [\[14\] **Glycine-modified growth hormone secretagogues identified in seized doping material.** PubMed / Drug Testing and Analysis, 2019. regulatory.](<https://pubmed.ncbi.nlm.nih.gov/30136411/>)
- [\[15\] **Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks** U.S. Food and Drug Administration. regulatory.](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)
- [\[16\] **FDA Evaluation of CJC-1295 Related Bulk Drug Substances for the December 4, 2024 Pharmacy Compounding Advisory Committee Meeting** U.S. Food and Drug Administration, 2024. regulatory.](<https://www.fda.gov/media/183819/download>)
- [\[17\] **openFDA Drugs@FDA query for CJC-1295** openFDA / U.S. Food and Drug Administration. database query.](<https://api.fda.gov/drug/drugsfda.json?search=openfda.substance_name:%22CJC-1295%22+OR+products.active_ingredients.name:%22CJC-1295%22&limit=1>)
- [\[18\] **NORDITROPIN somatropin injection prescribing information** U.S. Food and Drug Administration. official guidance.](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>)
- [\[19\] **Incorporation of D-Ala2 in growth hormone-releasing hormone-(1-29)-NH2 increases the half-life and decreases metabolic clearance in normal men.** PubMed / Journal of Clinical Endocrinology and Metabolism, 1994. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/7962295/>)
- [\[20\] **EGRIFTA WR- tesamorelin kit** DailyMed / National Library of Medicine. official guidance.](<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75>)
- [\[21\] **Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group.** The Journal of clinical endocrinology and metabolism, 1996 Mar. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/8772599/>)

[PepFlow library coverage](<https://pepflow.app/research/peptide-library/>)

## Quick facts

**Family**

GH/IGF axis peptide

**Tier**

B

**Evidence**

65% Moderate

**Safety**

Moderate Data

**FDA status**

Not Approved

**Injectable 503A**

Flagged

**Citations**

[21 citations](<https://pepflow.app/peptides/cjc-1295/#published-research>)

**Updated**

August 11, 2026

### Potential benefits

- GH-axis stimulation and IGF-1 biomarker response
- Lean-mass and fat-loss support
- Exercise recovery and training adaptation
- Sleep quality
- Anti-aging and vitality support

### Common side effects

- Injection-site pain or swelling
- Flushing or warmth
- Low blood pressure

### Also known as

- CJC 1295
- Long-acting CJC-1295
- Long-acting GHRH analog
- Albumin-binding GHRH analog

## Related

- [Peptide Label Key](<https://pepflow.app/peptide-label-legend/>)
- [CJC 1295 DAC vs No DAC: Make Your Choice](<https://pepflow.app/blog/cjc-1295-dac-vs-no-dac/>)
- [CJC-1295 dosage guide](<https://pepflow.app/peptides/cjc-1295/dosage/>)
- [Long-Acting GH Stack](<https://pepflow.app/stacks/cjc-1295-ipamorelin/>)
